{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:01Z","timestamp":1740107461603,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["# P30 CA33572"],"award-info":[{"award-number":["# P30 CA33572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Patients<\/jats:title>\n<jats:p>\nTreating physicians and advanced practice partners identified women who developed infections while on treatment with pertuzumab and trastuzumab alone or in combination with chemotherapy and enrolled them onto this registry trial.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections. The median age was 48\u00a0years. Twenty-four patients received neoadjuvant therapy, 17 were treated for metastatic disease, and 7 were treated in the adjuvant setting. Pertuzumab and trastuzumab were combined with carboplatin and docetaxel in 24 (49%) patients, docetaxel in 10 (21%), nab-paclitaxel in 12 (24%), and without other agents in 2 (4%). Granulocyte growth factors were administered in 24 (49%) patients and no patients were documented to be neutropenic. Folliculitis developed in 25 (52%) patients and was counted as a single infection. Abscesses developed at a number of sites in 24 (49%) patients, including a septic knee requiring total knee replacement. Paronychia occurred in 7 (15%) patients, and 5 (10%) developed cellulitis. When cultures were obtained, Gram-positive cocci were consistently identified. Hypogammaglobulinemia was documented in 14 (36%) of the 33 patients tested.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00280-019-03970-8","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T11:45:40Z","timestamp":1571831140000},"page":"501-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-1934","authenticated-orcid":false,"given":"Joanne E.","family":"Mortimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kruper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Wai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeet","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"3","key":"3970_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-014-3190-5","volume":"148","author":"J Mortimer","year":"2014","unstructured":"Mortimer J, Jung J, Yuan Y, Kruper L, Stewart D, Chung S, Yu K, Mendelsohn M, D\u2019Apuzzo M, Tegtmeier B et al (2014) Skin\/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Res Treat 148(3):563\u2013570","journal-title":"Breast Cancer Res Treat"},{"issue":"9816","key":"3970_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, G\u00f3mez H, Dinh P, Fauria K, Van Dooren V et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet 379(9816):633\u2013640","journal-title":"The Lancet"},{"issue":"8","key":"3970_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734","journal-title":"N Engl J Med"},{"issue":"2","key":"3970_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-014-3184-3","volume":"149","author":"T Funakoshi","year":"2015","unstructured":"Funakoshi T, Suzuki M, Muss H (2015) Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis. Breast Cancer Res Treat 149(2):321\u2013330","journal-title":"Breast Cancer Res Treat"},{"issue":"32","key":"3970_CR5","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1200\/JCO.2014.55.8437","volume":"32","author":"S Niraula","year":"2014","unstructured":"Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF (2014) Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32(32):3634\u20133642","journal-title":"J Clin Oncol"},{"issue":"20","key":"3970_CR6","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2003.04.537","volume":"21","author":"LA Ladewski","year":"2003","unstructured":"Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT et al (2003) Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 21(20):3859\u20133866","journal-title":"J Clin Oncol"},{"issue":"16","key":"3970_CR7","first-page":"1752","volume":"167","author":"TJ Moore","year":"2007","unstructured":"Moore TJ, Cohen MR, Furberg CD (2007) Serious adverse drug events reported to the food and drug administration, 1998\u20132005. JAMA Internal Med 167(16):1752\u20131759","journal-title":"JAMA Internal Med"},{"issue":"6","key":"3970_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.pharep.2016.07.003","volume":"68","author":"M Zaborowska-Szmit","year":"2016","unstructured":"Zaborowska-Szmit M, Kowalski DM, Pi\u00f3rek A, Krzakowski M, Szmit S (2016) A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. Pharmacol Rep 68(6):1140\u20131148","journal-title":"Pharmacol Rep"},{"issue":"2","key":"3970_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12253-017-0238-y","volume":"24","author":"G Rubovszky","year":"2018","unstructured":"Rubovszky G, Budai B, Ganofszky E, Horv\u00e1th Z, Juhos \u00c9, Madaras B, Nagy T, Szab\u00f3 E, Pint\u00e9r T, T\u00f3th E et al (2018) Predictive value of early skin rash in cetuximab-based therapy of advanced biliary tract cancer. Pathol Oncol Res 24(2):237\u2013244","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"3970_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw037","volume":"108","author":"A Sonnenblick","year":"2016","unstructured":"Sonnenblick A, de Azambuja E, Agbor-tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C et al (2016) Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial. JNCI J Natl Cancer Inst 108(8):1\u20138","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"26","key":"3970_CR11","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","volume":"35","author":"A Urruticoechea","year":"2017","unstructured":"Urruticoechea A, Rizwanullah M, Im S-A, Ruiz ACS, L\u00e1ng I, Tomasello G, Douthwaite H, Crnjevic TB, Heeson S, Eng-Wong J et al (2017) Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol 35(26):3030\u20133038","journal-title":"J Clin Oncol"},{"issue":"28","key":"3970_CR12","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","volume":"36","author":"M Rimawi","year":"2018","unstructured":"Rimawi M, Ferrero J-M, Haba-Rodriguez JDL, Poole C, Placido SD, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor\u2013positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36(28):2826\u20132835","journal-title":"J Clin Oncol"},{"issue":"6","key":"3970_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im Y-H, Tseng L-M, Liu M-C, Lluch A, Staros\u0142awska E, de la Haba-Rodriguez J, Im S-A, Pedrini JL et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791\u2013800","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03970-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:12:22Z","timestamp":1603235542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03970-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["3970"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03970-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This review was approved by the Institutional Review Board and was a chart review study which did not require informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}